Search
+
    The Economic Times daily newspaper is available online now.

    Soaring high: Lincoln Pharmaceuticals maintains a solid growth trajectory

    Synopsis

    Lincoln Pharma expects Rs 150 crore in sales from the recently-acquired Cephalosporin plant.

    "The company continues to remain net debt-free after multiple expansions and acquisitions," said Mahendra Patel, MD of Lincoln Pharmaceuticals Ltd.Agencies
    "The company continues to remain net debt-free after multiple expansions and acquisitions," said Mahendra Patel, MD of Lincoln Pharmaceuticals Ltd.
    Lincoln Pharmaceuticals Limited expects Rs 150 crore sales from the Cephalosporin plant in the next three years.

    The company invested Rs 30 crore in the Cephalosporin plant, including acquisition and subsequent capacity expansion using internal accruals.

    Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd, said, “FY23 is going to be a growth year for the company. Commercial production from the Mehsana facility for expansion in Cephalosporin products and exports to the EU and Australian markets are expected to commence in the current fiscal. The company continues to remain net debt-free after multiple expansions and acquisitions.”

    For Q1FY23, the company reported a net profit of Rs 15 crore, EBITDA of Rs 23.4 crore and total income of Rs 130 crore. Exports in Q1FY23 were reported at Rs 66.08 crore.

    The company reported robust financial and operational performance during FY12-FY22 with CAGR growth— 30 per cent profits, 20 per cent EBITDA and 10 per cent revenue. The company exports to over 60 countries.
    Download The Economic Times News App to get Daily Market Updates & Live Business News.
    ...more
    The Economic Times

    Stories you might be interested in